The Future of Healthcare
VitaX envisions a future where innovation and technology-democratization transform healthcare challenges to opportunities for global economic growth. Innovation in biotechnology, from omics to bio-robotics to AI/ML, will improve future generations’ survival by addressing health and climate change challenges. Technology democratization will empower equality, free global economic reform, and fair distribution of wealth across nations and technology verticals.
VitaX is a medtech and healthtech venture studio on a mission to transform innovation into sustainable economic growth by offering unmatched subject matter expertise, strategic and agile business acumen, and direct operations experience.
We work with Multinational Companies (MNCs) and R&D institutions to discover emerging opportunities to supply unmet demands in the medical and health technology markets. Our global network includes over 10 leading R&D institutions and 2 major pharma and medical device MNCs.
Like a pyramid, the foundation of any successful science startup must be set on four pillars. Two of them mostly depend on financial support, which are R&D and product development. The third pillar depends on attaining appropriate approval from regulatory agencies (RAs), like the FDA. The fourth is to protect the intellectual property behind the value proposition by working with federal agencies (FAs), like the USPTO and WIPO.
The medtech and healthtech markets are largely regulated by NGOs, professional societies, academic consortia, and patient-awareness networks. Startups in growth stages need strategic exposure and engagement with the global community in order to establish fast and scalable paths to enter new markets.
What We Do
VENTURE BUILDING SERVICES
Strategic Technology Planning
By leveraging smart and trustless licensing and joint-venture scenario plans in favor of resilient and economically efficient value-chains.
Go to Market Research
Identifying optimum go to market routes, research, and synergy exploration in secondary and indirect markets.
Early capitalization of intellectual assets through excellence in innovation, global market insights, and early engagement with regulatory bodies.
Health Technology Assessment
Third party HTA studies for emerging medical and health technologies and their competitive landscape
Access to Global Markets
Through our network of native industry and subject-matter experts in MENA, Europe, India, and Japan
Supply Chain Capability
Realistic supply chain capability models and assessment to minimize macro risks and maintain sustainable capacity growth
Get an innovation-led capital growth strategy for your startup
Does your startup have or is planning to have patents and/or trademarks? What’s the best strategy to create real innovation-led capital growth?